Zolmitriptan is under clinical development by PassPort Technologies Inc (USA) and currently in Phase I for Migraine. According to GlobalData, Phase I drugs for Migraine have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zolmitriptan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zolmitriptan overview

Zolmitriptan is under development for the treatment of acute migraine. It is administered by transdermal route as patch. The therapeutic candidate is developed based on PassPort technology. It acts by targeting  5-HT1B/D receptors.

PassPort Technologies Inc (USA) overview

PassPort Technologies is focused on the development of drug delivery systems. PassPort Technologies is headquartered in San Diego, California, the US.

For a complete picture of Zolmitriptan’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.